MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,818.93
+0.58%
NASDAQ 100
$31,224.47
+0.48%
DOW JONES
$51,521.00
+0.49%
NASDAQ Composite
$27,599.79
+0.45%
RUSSELL 2000
$2,813.40
-0.72%
CBOE VIX
$15.01
-3.29%
Sector Heatmap
Technology-0.30%
Financials-0.48%
Healthcare+1.03%
Consumer Cycl-0.32%
Consumer Staples-0.12%
Energy-0.58%
Industrials-2.18%
Materials-1.51%
Real Estate-1.29%
Utilities-0.02%
Comm Services-0.35%
OBIO — Orchestra BioMed Holdings, Inc. Ordinary Shares
NasdaqOrchestra BioMed Holdings, Inc. Ordinary Shares
$5.66
-0.18(-3.08%)
- O
- 5.79
- H
- 5.86
- L
- 5.64
- V
- 241.2K
⏱️ End-of-day dataAs of Oct 7, 2026
OBIO — Latest News & Headlines
7 Stories$OBIO stock is down 9% today. Here's what we see in our data. - Quiver Quantitative
$OBIO stock is down 9% today. Here's what we see in our data. Quiver Quantitative
A pacemaker therapy trial for hard-to-control blood pressure enrolled 330 people - Stock Titan
A pacemaker therapy trial for hard-to-control blood pressure enrolled 330 people Stock Titan
Biotech Stocks At 52-Week Highs - KOD, MASS, OBIO, CDNA, PMVP - RTTNews
Biotech Stocks At 52-Week Highs - KOD, MASS, OBIO, CDNA, PMVP RTTNews
H.C. Wainwright reiterates Orchestra BioMed stock rating on trial enrollment - Investing.com
H.C. Wainwright reiterates Orchestra BioMed stock rating on trial enrollment Investing.com
A planned 15,000-share sale at Orchestra BioMed (OBIO) averages $6.36 per share. - Stock Titan
A planned 15,000-share sale at Orchestra BioMed (OBIO) averages $6.36 per share. Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks The Globe and Mail
Across 13 countries, Orchestra BioMed (OBIO) exceeds its blood-pressure trial enrollment target. - Stock Titan
Across 13 countries, Orchestra BioMed (OBIO) exceeds its blood-pressure trial enrollment target. Stock Titan